Cogent Biosciences, Inc.

NasdaqGS COGT

Cogent Biosciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 145.69

Cogent Biosciences, Inc. Price to Sales Ratio (P/S) is 145.69 on January 14, 2025, a 81.44% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Cogent Biosciences, Inc. 52-week high Price to Sales Ratio (P/S) is 219.03 on October 23, 2024, which is 50.34% above the current Price to Sales Ratio (P/S).
Cogent Biosciences, Inc. 52-week low Price to Sales Ratio (P/S) is 74.51 on January 26, 2024, which is -48.86% below the current Price to Sales Ratio (P/S).
Cogent Biosciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 150.97.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: COGT

Cogent Biosciences, Inc.

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive
Employees	164
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years